$NBIX
NEUROCRINE BIOSCIENCES INC

2013 Q1 Form 10-Q Financial Statement

#000119312513196338 Filed on May 02, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q1
Revenue $730.0K $11.27M
YoY Change -93.52% -9.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.400M $3.700M
YoY Change -8.11% 15.63%
% of Gross Profit
Research & Development $10.31M $9.388M
YoY Change 9.85% 28.3%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $13.71M $13.06M
YoY Change 4.95% 23.51%
Operating Profit -$12.98M -$1.792M
YoY Change 624.05% -192.42%
Interest Expense $100.0K $100.0K
YoY Change 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $900.0K $906.0K
YoY Change -0.66% -3.92%
Pretax Income -$12.10M -$900.0K
YoY Change 1244.44% -131.03%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.08M -$886.0K
YoY Change 1262.87% -130.74%
Net Earnings / Revenue -1654.11% -7.86%
Basic Earnings Per Share -$0.18 -$0.01
Diluted Earnings Per Share -$0.18 -$0.01
COMMON SHARES
Basic Shares Outstanding 66.60M shares 63.41M shares
Diluted Shares Outstanding 66.60M shares 63.41M shares

Balance Sheet

Concept 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $158.2M $181.1M
YoY Change -12.64% 48.93%
Cash & Equivalents $31.56M $76.94M
Short-Term Investments $126.7M $104.1M
Other Short-Term Assets $2.153M $2.079M
YoY Change 3.56% 22.29%
Inventory
Prepaid Expenses
Receivables $0.00 $1.800M
Other Receivables $0.00 $0.00
Total Short-Term Assets $160.4M $185.0M
YoY Change -13.29% 46.11%
LONG-TERM ASSETS
Property, Plant & Equipment $1.784M $1.837M
YoY Change -2.89% 41.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $17.40M $19.00M
YoY Change -8.42%
Other Assets $4.300M $4.300M
YoY Change 0.0% -29.51%
Total Long-Term Assets $23.53M $25.17M
YoY Change -6.51% 240.09%
TOTAL ASSETS
Total Short-Term Assets $160.4M $185.0M
Total Long-Term Assets $23.53M $25.17M
Total Assets $183.9M $210.1M
YoY Change -12.48% 56.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.460M $596.0K
YoY Change 144.97% 19.2%
Accrued Expenses $6.577M $6.967M
YoY Change -5.6% 18.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.88M $36.63M
YoY Change -62.11% -25.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $152.0K $124.0K
YoY Change 22.58% -99.8%
Total Long-Term Liabilities $152.0K $124.0K
YoY Change 22.58% -99.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.88M $36.63M
Total Long-Term Liabilities $152.0K $124.0K
Total Liabilities $38.97M $66.31M
YoY Change -41.23% -40.26%
SHAREHOLDERS EQUITY
Retained Earnings -$731.7M -$725.6M
YoY Change 0.85%
Common Stock $67.00K $66.00K
YoY Change 1.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $145.0M $143.8M
YoY Change
Total Liabilities & Shareholders Equity $183.9M $210.1M
YoY Change -12.48% 56.82%

Cashflow Statement

Concept 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$12.08M -$886.0K
YoY Change 1262.87% -130.74%
Depreciation, Depletion And Amortization $200.0K $200.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities $1.912M -$11.20M
YoY Change -117.07% 30.58%
INVESTING ACTIVITIES
Capital Expenditures $59.00K $404.0K
YoY Change -85.4% 1920.0%
Acquisitions
YoY Change
Other Investing Activities -$35.00M -$44.80M
YoY Change -21.88% 112.32%
Cash From Investing Activities -$35.08M -$45.22M
YoY Change -22.42% 113.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $966.0K $83.00M
YoY Change -98.84% 145514.04%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 966.0K 83.25M
YoY Change -98.84% 145957.89%
NET CHANGE
Cash From Operating Activities 1.912M -11.20M
Cash From Investing Activities -35.08M -45.22M
Cash From Financing Activities 966.0K 83.25M
Net Change In Cash -32.20M 26.83M
YoY Change -220.0% -190.47%
FREE CASH FLOW
Cash From Operating Activities $1.912M -$11.20M
Capital Expenditures $59.00K $404.0K
Free Cash Flow $1.853M -$11.61M
YoY Change -115.96% 34.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66732368 shares
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76940000
CY2012Q1 nbix Cease Use Liability
CeaseUseLiability
2528000
CY2013Q1 us-gaap Deferred Gain On Sale Of Property
DeferredGainOnSaleOfProperty
23200000
CY2013Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
108740000
CY2013Q1 us-gaap Other Assets Current
OtherAssetsCurrent
2153000
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
144953000
CY2013Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
144133000
CY2013Q1 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2
66000
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2013Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
144089000
CY2013Q1 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2
66000
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66712374 shares
CY2013Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
108740000
CY2013Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
8000
CY2013Q1 us-gaap Liabilities
Liabilities
38971000
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1460000
CY2013Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2189000
CY2013Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
152000
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q1 us-gaap Long Term Investments
LongTermInvestments
17410000
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-731748000
CY2013Q1 us-gaap Assets
Assets
183924000
CY2013Q1 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
22000
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
183924000
CY2013Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4335000
CY2013Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31555000
CY2013Q1 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
66000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66712374 shares
CY2013Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-44000
CY2013Q1 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
20067000
CY2013Q1 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
496000
CY2013Q1 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2996000
CY2013Q1 nbix Cease Use Liability
CeaseUseLiability
3492000
CY2008Q4 us-gaap Deferred Gain On Sale Of Property
DeferredGainOnSaleOfProperty
39100000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50107000
CY2011Q4 nbix Cease Use Liability
CeaseUseLiability
2592000
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
67492000
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6577000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13878000
CY2013Q1 us-gaap Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
CY2013Q1 us-gaap Short Term Investments
ShortTermInvestments
126679000
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
67000
CY2013Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1878000
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Assets Current
AssetsCurrent
160395000
CY2013Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1784000
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
876678000
CY2013Q1 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
144089000
CY2013Q1 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3156000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2162000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
154372000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
109741000
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2
35000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
109739000
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2
35000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66446888 shares
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
67492000
CY2012Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
14089000
CY2012Q4 us-gaap Liabilities
Liabilities
41607000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
911000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2919000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
152000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Long Term Investments
LongTermInvestments
480000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-719673000
CY2012Q4 us-gaap Assets
Assets
195979000
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
33000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
195979000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4335000
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63754000
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
35000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66446888 shares
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8094000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15646000
CY2012Q4 us-gaap Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
109259000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
66000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1840000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Assets Current
AssetsCurrent
189264000
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1900000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
873981000
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
109739000
CY2012Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3133000
CY2012Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
20872000
CY2012Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
589000
CY2012Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
3097000
CY2012Q4 nbix Cease Use Liability
CeaseUseLiability
3686000
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
83000000
CY2012Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
10900000 shares
CY2012Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
8.10
CY2010Q4 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
600000
CY2010Q4 nbix Subleased Agreement Area
SubleasedAgreementArea
16000 sqft
CY2010Q4 nbix Sublease Term
SubleaseTerm
P3Y
CY2012Q3 nbix Subleased Agreement Area
SubleasedAgreementArea
17000 sqft
CY2007 us-gaap Sale Leaseback Transaction Lease Terms
SaleLeasebackTransactionLeaseTerms
The Company entered into a lease agreement (Lease) with DMH Campus Investors, LLC (DMH) whereby it leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building.
CY2007 us-gaap Proceeds From Sale Of Real Estate
ProceedsFromSaleOfRealEstate
61000000
CY2007 nbix Mortgage Loans Assumed By Purchaser
MortgageLoansAssumedByPurchaser
47700000
CY2007 nbix Property Plant Equipment Selling Price
PropertyPlantEquipmentSellingPrice
109000000
CY2007 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2013Q1 dei Trading Symbol
TradingSymbol
NBIX
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
38000
CY2013Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
66501000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12975000
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2013Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
13000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12117000
CY2013Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
795000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
966000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1732000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-968000
CY2013Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
13000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
300000 shares
CY2013Q1 us-gaap Investment Income Net
InvestmentIncomeNet
103000
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
175000
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1912000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35077000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-730000
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-32199000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3392000
CY2013Q1 us-gaap Licenses Revenue
LicensesRevenue
730000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10313000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
966000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
13705000
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1700000
CY2013Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-639000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2013Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
31470000
CY2013Q1 us-gaap Revenues
Revenues
730000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
800000 shares
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66600000 shares
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-12075000
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
900000
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-14090000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
700000 shares
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</font></p> </div>
CY2013Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-42000
CY2013Q1 nbix Deferred Gain Recognized
DeferredGainRecognized
800000
CY2013Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
782000
CY2013Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-194000
CY2013Q1 nbix Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount
PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount
2000000 shares
CY2013Q1 nbix Lease Expiration Year
LeaseExpirationYear
2019
CY2013Q1 nbix Share Based Compensation Arrangement By Share Based Payment Award Contractual Life
ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualLife
P10Y
CY2013Q1 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
194000
CY2012Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
80000
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83253000
CY2012Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1000
CY2012Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
75385000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1792000
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
83253000
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2012Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
25000
CY2012Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-926000
CY2012Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
783000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1426000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1999000
CY2012Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2012Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
94000 shares
CY2012Q1 us-gaap Investment Income Net
InvestmentIncomeNet
121000
CY2012Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
152000
CY2012Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
300000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11204000
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45216000
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9237000
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
404000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26833000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3671000
CY2012Q1 us-gaap Licenses Revenue
LicensesRevenue
9238000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9388000
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
13059000
CY2012Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
30548000
CY2012Q1 us-gaap Revenues
Revenues
11267000
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1400000
CY2012Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-623000
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63409000 shares
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2400000 shares
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-886000
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
906000
CY2012Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
515000
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1300000 shares
CY2012Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
25000 shares
CY2012Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-40000
CY2012Q1 nbix Deferred Gain Recognized
DeferredGainRecognized
800000
CY2012Q1 nbix Sponsored Research And Development Revenue
SponsoredResearchAndDevelopmentRevenue
2029000
CY2012Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
758000
CY2012Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-64000
CY2012Q1 nbix Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount
PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount
1400000 shares
CY2012Q1 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
64000

Files In Submission

Name View Source Status
0001193125-13-196338-index-headers.html Edgar Link pending
0001193125-13-196338-index.html Edgar Link pending
0001193125-13-196338.txt Edgar Link pending
0001193125-13-196338-xbrl.zip Edgar Link pending
d499443d10q.htm Edgar Link pending
d499443dex311.htm Edgar Link pending
d499443dex312.htm Edgar Link pending
d499443dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
nbix-20130331.xml Edgar Link completed
nbix-20130331.xsd Edgar Link pending
nbix-20130331_cal.xml Edgar Link unprocessable
nbix-20130331_def.xml Edgar Link unprocessable
nbix-20130331_lab.xml Edgar Link unprocessable
nbix-20130331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending